Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

European Neurology

Volumn 61, Issue 5, 2009, Pages 278-284

  Vaneckova, Manuela ^a,c   Seidl, Zdenek ^a,b   Krasensky, Jan ^a   Havrdova, Eva ^a   Horakova, Dana ^a   Dolezal, Ondrej ^a   Burgetova, Andrea ^a   Masek, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Medical College   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Brain atrophy; Lesion load; Magnetic resonance imaging; Multiple sclerosis; Prediction of clinical disability

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; CLASSIFICATION; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LESION LOAD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ATROPHY; BRAIN; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 62849087798     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000206852     Document Type: Article

References (35)

1. Paty DW, Oger JF, Kastrukoff LF, et al: MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:1579-1616.
2. Tintore M, Rovira A, Martinez MJ, et al: Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-706.
3. Grossman RI, McGowan JC: Perspectives on multiple sclerosis. AJNR Am J Neuroradiol 1998;19:1251-1265.
4. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
5. Glad S, Nyland H, Myhr KM: Benign multiple sclerosis. Acta Neurol Scand 2006;113(suppl 183):55-57.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick RM, Mork S, Bo L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
7. Lassmann H: Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002;104:168-171.
8. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodrigez M, Lassman H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
9. Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005;58:840-846.
10. Barkhof F: MRI in multiple sclerosis: correlation with Expanded Disability Status Scale (EDSS). Mult Scler 1999;5:283-286.
11. Ciccarelli O, Brex AP, Thompson AJ, Miller DH: Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. J Neurol 2002;249:18-24.
12. Vaneckova M, Seidl Z, Krasensky J, et al: Sledovani objemu lozisek u roztrousene sklerozy mozkomisni magnetickou rezonanci. Ces Slov Neurol Neurochir 2002;3:175-179.
13. Vaneckova M, Seidl Z, Krasensky J, et al: The predictive ability of magnetic resonance imaging to progression of clinical disability in patients with multiple sclerosis. J Neurol 2007;254(suppl 3):III/163.
14. Miller DH, Barkhof F, Nauta JJ: Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
15. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF: Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetisation transfer contrast and delayed imaging. Brain 1997;120:1749-1761.
16. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH: T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurol 2001;8:31-42.
17. Filippi M, Capra R, Campi A, et al: Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526-530.
18. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani P, Comi G: Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55:1714-1718.
19. Rudick RA, Fisher E, Lee JC: Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704.
20. Yulin GE, Grossman RI, Udupa JK, Babb JS, Nyul LG, Kolson LD: Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Neuroradiology 2001;3:606-610.
21. Dolezal O, Dwyer MG, Horakova D, et al: Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. Int Rev Neurobiol 2007;79:475-489.
22. Bo L, Geurts JJG, Mork SJ, van der Valk P: Grey matter pathology in multiple sclerosis. Acta Neurol Scand 2006:113(suppl 183):48-50.
23. 1-weighted, magnetization transfer and diffusion tensor MR imaging. Am J Neuroradiol 2001;22:1462-1467.
24. Miller DH, Thompson AJ, Filippi M: Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407-1419.
25. Wuerfel J, Bellman-Strobl J, Brunecker P, et al: Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004;127(Pt1):111-119.
26. Vrenken H, Rombouts SA, Pouwels PJ, Barkhof F: Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. AJNR Am J Neuroradiol 2006;27:868-874.
27. Anderson VA, Fox NC, Miller DH: Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Res Imaging 2006;23:605-618.
28. Schreiber K, Sørensen PS, Koch-Henriksen N, et al: Correlations of brain MRI parameters to disability in multiple sclerosis. Acta Neurol Scand 2001;104:24-30.
29. Molyneux PD, Filippi M, Barkhof F, et al: Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339.
30. Miller DH, Grossman RI, Reingold SC, McFarland HF: The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
31. Fisher E, Rudick RA, Cutter G, et al: Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-377.
32. Zivadinov R, Rudick RA, De Masi R, et al: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247.
33. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
34. Bielekova B, Kadom N, Fisher E, et al: MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005;65:1071-1076.
35. Filippi M, Grossman RI: MRI techniques to monitor MS evolution: the present and the future. Neurology 2002;58:1147-1153.